Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $(54,515) | $(36,459) |
| General and administrative | (15,509) | (11,026) |
| Total operating expenses | (70,024) | (47,485) |
| Operating loss | (70,024) | (47,485) |
| Interest expense | (2,269) | (18) |
| Other income, net | 3,208 | 7,097 |
| Loss before income tax | (69,085) | (40,406) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's R&D?
- MoonLake Immunotherapeutics (MLTX) reported R&D of $54.52M in Q1 2026.
- How has MoonLake Immunotherapeutics's R&D changed year-over-year?
- MoonLake Immunotherapeutics's R&D increased by 49.5% year-over-year, from $36.46M to $54.52M.
- What is the long-term trend for MoonLake Immunotherapeutics's R&D?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's R&D has grown at a 68.7% compound annual growth rate (CAGR), from $42.25M to $202.86M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about MoonLake Immunotherapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude